I JIA- forsøget var de få transaminase- stigninger små og ens hos placebo - og adalimumab- eksponerede patienter, og de fleste forekom i kombination med methotrexat.
In the JIA trial the few transaminase elevations were small and similar in the placebo and adalimumab exposed patients, and mostly occurred in combination with methotrexate.